Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriations

This article was originally published in The Gray Sheet

Executive Summary

Senate adopts the conference report on the FY 2000 agriculture spending measure (HR 1906) Oct. 13 by a 74-26 vote. President Clinton has said he will sign the legislation, which was adopted by the House on Oct. 1. The $1.18 bil. FDA portion of the bill earmarks $55.5 mil. and 522 full-time employees to premarket application review activities at the Center for Devices and Radiological Health (1"The Gray Sheet" Oct. 11, In Brief)

You may also be interested in...



Device center's FY 2000 budget

Senate is expected to vote on the conference report to the fiscal 2000 agriculture appropriations bill (HR 1906) Oct. 12. FDA's Center for Devices and Radiological Health would receive $164.3 mil. in funding under the report, which was adopted by the House on Oct. 1. The legislation earmarks $1 mil. for premarket review, enforcement and oversight activities related to users and manufacturers of all reprocessed single-use devices. At least $55.5 mil. is designated for PMA application review activities to meet statutory review times

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel